Insider Selling: Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Sells $19,916.48 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Director Deborah M. Messemer sold 9,136 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $2.18, for a total value of $19,916.48. Following the completion of the sale, the director now owns 157,629 shares in the company, valued at approximately $343,631.22. This trade represents a 5.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Allogene Therapeutics Stock Performance

NASDAQ ALLO opened at $2.02 on Friday. The company has a market capitalization of $423.54 million, a PE ratio of -1.29 and a beta of 0.83. The company has a 50-day simple moving average of $2.57 and a 200 day simple moving average of $2.58. Allogene Therapeutics, Inc. has a 52-week low of $1.99 and a 52-week high of $5.78.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler cut their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research note on Friday, November 8th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.73.

Institutional Investors Weigh In On Allogene Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ALLO. Perceptive Advisors LLC purchased a new position in shares of Allogene Therapeutics during the 2nd quarter valued at $6,349,000. Lynx1 Capital Management LP purchased a new position in shares of Allogene Therapeutics in the 2nd quarter worth about $5,192,000. Renaissance Technologies LLC boosted its stake in Allogene Therapeutics by 340.4% in the second quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock worth $4,073,000 after buying an additional 1,351,055 shares in the last quarter. Zacks Investment Management purchased a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at $1,446,000. Finally, Dimensional Fund Advisors LP lifted its stake in Allogene Therapeutics by 24.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after purchasing an additional 507,021 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).